Compare SFWL & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFWL | LONA |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.5M | 49.7M |
| IPO Year | 2021 | 2020 |
| Metric | SFWL | LONA |
|---|---|---|
| Price | $3.75 | $4.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $16.67 |
| AVG Volume (30 Days) | 4.5K | ★ 82.9K |
| Earning Date | 09-15-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $2.21 |
| 52 Week High | $12.00 | $14.21 |
| Indicator | SFWL | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 28.17 | 39.17 |
| Support Level | $0.80 | $4.39 |
| Resistance Level | $9.94 | $9.78 |
| Average True Range (ATR) | 0.51 | 0.45 |
| MACD | -0.60 | -0.01 |
| Stochastic Oscillator | 12.94 | 2.87 |
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services. The company's operations are based in the PRC. Its integrated logistics solutions are comprised of three business streams: B2B freight transportation services; cloud storage services; and value-added services. The company derives maximum revenue from Transportation, followed by Warehouse storage management services. The solutions provides by the company are : Internet TV; Electronic communication; Textiles and Apparel; Automotive parts; and e-commerce.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.